Therapeutic Asset Ratings

435 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Irinotecan Multiple Myeloma	OHSU Knight Cancer Institute	P3	B (60)
Abemaciclib Non-Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	B (60)
Abemaciclib Stage III Pancreatic Cancer AJCC v8	OHSU Knight Cancer Institute	P2	B (60)
ALECTINIB Sarcoma	OHSU Knight Cancer Institute	P2	B (60)
ALECTINIB Breast Cancer	OHSU Knight Cancer Institute	P2	B (60)
Allopurinol Acute Myeloid Leukemia	OHSU Knight Cancer Institute	P2	B (60)
Atezolizumab Malignant Pancreatic Neoplasm	OHSU Knight Cancer Institute	P2	B (60)
Carboplatin Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	OHSU Knight Cancer Institute	P2	B (60)
Dasatinib Metastatic Pancreatic Adenocarcinoma	OHSU Knight Cancer Institute	P2	B (60)
Eloxatin Recurrent Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	B (60)
Eloxatin Hodgkins Lymphoma	OHSU Knight Cancer Institute	P2	B (60)
Entrectinib Sarcoma	OHSU Knight Cancer Institute	P2	B (60)
Gdc-0449 Anatomic Stage IV Breast Cancer AJCC v8	OHSU Knight Cancer Institute	P2	B (60)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Ovarian Carcinoma	OHSU Knight Cancer Institute	P2	B (60)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	P2	B (60)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Prostate Carcinoma	OHSU Knight Cancer Institute	P2	B (60)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Recurrent Prostate Carcinoma	OHSU Knight Cancer Institute	P2	B (60)
Ipilimumab Non-Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	B (60)
Irinotecan Chronic Myelomonocytic Leukemia	OHSU Knight Cancer Institute	P2	B (60)
Letrozole Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	P2	B (60)
Letrozole Sarcoma	OHSU Knight Cancer Institute	P2	B (60)
Mosunetuzumab High Grade B-Cell Lymphoma	OHSU Knight Cancer Institute	P2	B (60)
Niraparib Malignant Pancreatic Neoplasm	OHSU Knight Cancer Institute	P2	B (60)
Osimertinib Breast Cancer	OHSU Knight Cancer Institute	P2	B (60)
Palbociclib Prostate Carcinoma	OHSU Knight Cancer Institute	P2	B (60)

Showing 101 to 125 of 435 assets

PreviousPage 5 of 18Next